Upcoming Clinical Trials
EYEPOINT PHASE III
Pathology: Tx naïve nAMD and ongoing tx nAMD
Description: A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept, in Subjects with Wet AMD
OCU-002
Pathology: Intermediate dAMD and small lesion GA
Description: Phase 2 Multicenter, Randomized, Double-Masked, Dose Response Study Using Ocustatin in Subjects with Intermediate Age-Related Macular Degeneration
ONL1204-GA-002
Pathology: Geographic Atrophy
Description: A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients with Geographic Atrophy (GA) associated with Age-related Macular Degeneration (AMD)
R3918-AMD-2297
Pathology: Geographic Atrophy
Description: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD)
VGFTe-HD-OD-2331
Pathology: Tx Naïve nAMD/DME and ongoing nAMD/DME
Description: Real-world patient characteristics, treatment patterns, and outcomes among patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) treated with aflibercept 8 mg in the United States.
VGFTe-HD-RVO-2335
Pathology: HRVO, CRVO, BRVO
Description: A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 mg Aflibercept in Participants with Macular Edema Secondary to Retinal Vein Occlusion